Capsaicin

Generic Name: Capsaicin

Brand Names: Capzasin Quick Relief, Capzasin-HP, Castiva Warming, Dendracin Neurodendraxcin, Lidopro, Medi-derm, Medi-derm With Lidocaine, Medrox, Qutenza, Rematex, Xoten-C, Zostrix

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₇NO_₃

CAS Number: 404-86-4

Unique Ingredient Identifier: S07O44R1ZM

Background: Capsaicin is most often used as a topical analgesic and exists in many formulations of cream, liquid, and patch preparations of various strengths; however, it may also be found in some dietary supplements. Capsaicin is a naturally-occurring botanical irritant in chili peppers, synthetically derived for pharmaceutical formulations. The most recent capsaicin FDA approval was Qutenza, an 8% capsaicin patch dermal-delivery system, indicated for neuropathic pain associated with post-herpetic neuralgia.

Indication: The capsaicin 8% patch is indicated in the treatment of neuropathic pain associated with post-herpetic neuralgia. There are multiple topical capsaicin formulations available, including creams and solutions, indicated for temporary analgesia in muscle and join pain as well as neuropathic pain.

Associated Conditions: Back Pain Lower Back, Back pain, Bursitis, Contusions, Inflammatory Reaction caused by Rheumatism, Muscle Cramps, Musculoskeletal Pain, Neuropathic Pain, Osteoarthritis (OA), Pain caused by Rheumatism, Periarthritis, Soft Tissue Injury, Tendinitis, Acute nonspecific tenosynovitis, Articular inflammation

Clinical Trials

Thermosensitivity of a Topical Palmitated Formulation of Capsaicin

Early Phase 1

Completed

Conditions: Pain Management

Interventions: Drug: Capsaicin 0.1% Cream
Drug: Capsaicin Palmitate 0.25% Cream
Drug: Placebo Cream

First Posted Date: 2022-12-14

Last Posted Date: 2024-03-21

Lead Sponsor: Carilion Clinic

Target Recruit Count: 52

Registration Number: NCT05649228

Locations: 🇺🇸
Carilion Clinic, Roanoke, Virginia, United States

Qutenza Versus Duloxetine in Chemotherapy-induced Peripheral Neuropathy (CIPN)

Not Applicable

Recruiting

Conditions: Qutenza
CIPN - Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Duloxetine

Interventions: Drug: Qutenza
Drug: Duloxetine

First Posted Date: 2022-09-29

Last Posted Date: 2023-12-15

Lead Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Target Recruit Count: 102

Registration Number: NCT05560516

Locations: 🇳🇱
Amsterdam UMC, locatie VUMC, Amsterdam, Netherlands

Capsaicin for Cerebral Perfusion Augmentation

Phase 2

Completed

Conditions: Cerebral Circulatory Disorder

Interventions: Drug: Capsaicin

First Posted Date: 2022-09-16

Last Posted Date: 2023-03-14

Lead Sponsor: Instituto Mexicano del Seguro Social

Target Recruit Count: 20

Registration Number: NCT05543837

Locations: 🇲🇽
Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico

Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy

Phase 2

Completed

Conditions: Nausea Gravidarum
Hyperemesis Gravidarum
Vomiting of Pregnancy

Interventions: Drug: Capsaicin Topical Cream
Drug: Metoclopramide
Drug: Ondansetron
Drug: Lactated Ringers, Intravenous

First Posted Date: 2021-10-28

Last Posted Date: 2024-02-07

Lead Sponsor: Women and Infants Hospital of Rhode Island

Target Recruit Count: 30

Registration Number: NCT05098067

Locations: 🇺🇸
Women and Infants Hospital, Providence, Rhode Island, United States

The Prevalence of Local Immunoglobulin E (IgE) Elevation and Its Effect on Intranasal Capsaicin Therapy in the Non-allergic Rhinitis Population

Phase 3

Completed

Conditions: Non-allergic Rhinitis

Interventions: Drug: Intranasal capsaicin
Drug: topical lidocaine

First Posted Date: 2021-10-26

Last Posted Date: 2024-12-20

Lead Sponsor: The University of Texas Health Science Center, Houston

Target Recruit Count: 28

Registration Number: NCT05093478

Locations: 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States

Burning Mouth Syndrome - New Diagnostic Criteria and Treatment

Not Applicable

Conditions: Burning Mouth Syndrome

Interventions: Drug: Capsaicin Topical
Other: Placebo
Drug: Clonazepam 0.5 MG

First Posted Date: 2021-09-28

Last Posted Date: 2021-09-28

Lead Sponsor: Malmö University

Target Recruit Count: 40

Registration Number: NCT05059418

Study With Two Capsaicin Topic Treatments in Diabetic Neuropathy.

Phase 3

Completed

Conditions: Diabetic Neuropathy, Painful

Interventions: Drug: Capsaicin

First Posted Date: 2021-08-31

Last Posted Date: 2021-09-14

Lead Sponsor: Arafarma Group, S.A.

Target Recruit Count: 161

Registration Number: NCT05029297

Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery

Phase 3

Active, not recruiting

Conditions: Post Surgical Neuropathic Pain

Interventions: Drug: capsaicin 0.04% topical system
Drug: Qutenza (capsaicin) 8% topical system

First Posted Date: 2021-07-19

Last Posted Date: 2025-04-30

Lead Sponsor: Averitas Pharma, Inc.

Target Recruit Count: 409

Registration Number: NCT04967664

Locations: 🇪🇸
Clinica Gaias, Santiago de Compostela, Spain
🇪🇸
Hospital Clinico Universitario de Valencia, Valencia, Spain
🇵🇱
Linden Centrum Medyczne, Krakow, Poland

and more 61 locations